Last reviewed · How we verify
SB8
SB8 is a biosimilar of bevacizumab that inhibits vascular endothelial growth factor (VEGF) to block tumor angiogenesis and reduce blood supply to cancer cells.
SB8 is a biosimilar of bevacizumab that inhibits vascular endothelial growth factor (VEGF) to block tumor angiogenesis and reduce blood supply to cancer cells. Used for Metastatic colorectal cancer, Non-squamous non-small cell lung cancer, Metastatic breast cancer.
At a glance
| Generic name | SB8 |
|---|---|
| Also known as | SB8 (A proposed bevacizumab biosimilar) |
| Sponsor | Samsung Bioepis Co., Ltd. |
| Drug class | VEGF inhibitor (monoclonal antibody) / Bevacizumab biosimilar |
| Target | VEGF (Vascular Endothelial Growth Factor) |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
SB8 is a monoclonal antibody that binds to and neutralizes VEGF, a key signaling molecule that promotes the formation of new blood vessels. By blocking VEGF, SB8 prevents tumors from developing their own blood supply, thereby inhibiting tumor growth and metastasis. As a bevacizumab biosimilar developed by Samsung Bioepis, it is designed to have comparable efficacy and safety to the reference biologic.
Approved indications
- Metastatic colorectal cancer
- Non-squamous non-small cell lung cancer
- Metastatic breast cancer
- Renal cell carcinoma
Common side effects
- Hypertension
- Proteinuria
- Bleeding
- Thromboembolic events
- Gastrointestinal perforation
- Wound healing complications
Key clinical trials
- A Study Comparing SB8 and Avastin® in Patients With Advanced Non-squamous Non-small Cell Lung Cancer (PHASE3)
- Pharmacokinetic, Safety, Tolerability, and Immunogenicity Study of SB8 in Healthy Male Subjects (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- SB8 CI brief — competitive landscape report
- SB8 updates RSS · CI watch RSS
- Samsung Bioepis Co., Ltd. portfolio CI